Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


24. August 2020 | 06:58 CET

BioNTech, CureVac, Valeo Pharma - the license to print money

  • Covid-19

Those who solve problems or create desires can usually earn a lot of money. One of the most important requirements is that the solution is scalable and can be sold in large quantities. The solutions around the Corona pandemic are a particularly lucrative business, because there is enormous pressure to act from all sides. The sooner vaccines or other products are available, the sooner it will be possible to return to normal everyday life. While two German pharmaceutical companies are investing a lot of money in researching a vaccine, a Canadian competitor is taking an equally exciting and less risky route.

time to read: 2 minutes by Mario Hose


 

The springboard to Canada

Valeo Pharma is a Canadian pharmaceutical company specializing in the licensing, approval and distribution of drugs. Small and medium-sized biotech companies involved in research often have the problem of having to arrange for commercialization once the drug is finished. This is exactly where Valeo Pharma's strength is, because the company is not involved in research and focuses on sales with attractive margins. This eliminates the high costs and risks associated with research and allows management to focus on products that have already been successfully tested. First and foremost, the Canadian home market is the main sales market. Access to physicians is particularly important because they usually prescribe the drugs to patients.

The company already has eight different products in its portfolio and six more in the pipeline. Last week, Valeo Pharma announced that it will increase its equity by CAD 6.00 million as part of a financing deal. If demand is high, the consortium accompanying the measure may increase the volume to up to CAD 6.90 million. In times of the Corona pandemic, a well-filled bank account is helpful to be able to increase, train and equip the staff accordingly. As soon as a partner with a Covid-19 drug knocks on Valeo Pharma's door, the company can enter into negotiations stronger. Valeo Pharma's market capitalization on Friday was just CAD 70.3 million and has corresponding potential due to this comparatively low base.

Research is progressing

BioNTech has already been keeping investors busy for several months. Since the company has joined forces with Pfizer to develop a vaccine against Covid-19, the share price has increased significantly. The company is now valued at more than USD 17.3 billion on the stock exchange. In the past, the experts focused on individual cancer therapies and are now leading the field internationally in the fight against the Corona Pandemic together with several other teams of experts.

In a test involving 30,000 patients, 11,000 people have already received a dose of a drug with a high chance of success. The expectations are already high that a vaccine will be available from BioNTech in the foreseeable future. Nobody can estimate how much potential the stock still has in the short term and what valuation level can be maintained.

Highflyer with chances of success

CureVac is a newcomer to the stock market and already has a market capitalisation of almost USD 12 billion. The German company also belongs to the global elite in research and received financial support from the German government in the race against the pandemic. The EU is already negotiating with CureVac on the possible availability of 225 million vaccine doses. Against this background, high expectations are now included in the company valuation.

The coming days, weeks and months will be exciting. Supplying several billion people with appropriate vaccine doses will be a gigantic task for the industry. In addition, the distribution of vaccine doses is of great economic and political importance. It is therefore not surprising that the company's shares are currently trading heavily.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

23. September 2020 | 09:05 CET

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

  • Covid-19

When the Corona Pandemic started in November 2019 in Wuhan, China, nobody could have guessed the extent of the disease. Socially, economically and politically, Covid-19 has turned the world upside down. With increasing knowledge in dealing with the coronavirus, people around the globe are trying to come to terms with the new state of affairs - as best they can. On the stock market, there are numerous opportunities for investors to participate in further development in the fight against serious diseases.

Read

18. September 2020 | 06:00 CET

BioNTech, CureVac, EXMceuticals - reaching their goal with government support

  • Covid-19

In the fight against the spread of the Corona Pandemic, a great deal of commitment is required from companies. This situation also offers the opportunity to rethink and change existing work processes and procedures. Product ranges are being expanded and new possibilities and active ingredients are being sought to combat Covid-19. Above all, the common good of all is the primary focus of political institutions and for this reason they are not letting research-based companies down and are attracting them with special permits and subsidies. Ultimately, everyone around the world will likely benefit from this.

Read

11. September 2020 | 09:59 CET

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

  • Covid-19

Anyone working in the medical sector knows that the development of therapies and products usually costs a lot of time and especially a lot of money. In the race against the spread of the current Corona pandemic, there are major changes in the industry, because whoever comes to the market with a product first is de facto guaranteed high sales and profits. However, there is not much time left for the development of a vaccine against Covid-19 and to reduce the economic damage, researching companies have virtually unlimited amounts of money available. Whoever finds a solution against Covid-19 will certainly have the right team in the starting blocks in the fight against the subsequent Corona viruses.

Read